Teva's generic Advair may sit 'til 2018

Share this article:

September FDA draft guidance looked like it could make it easier for generics of GlaxoSmithKline's asthma/COPD medication Advair to hit the market. The issue at the time was that the guidance indicated generics rivals could bypass human trials in their pursuit of regulatory approval.

The guidance, however, does not address a mechanical challenge, which is the complexity of the inhaler itself, for which GSK has a patent until 2016.

The new news: Teva announced on Tuesday that it does not expect to drop its generic Advair into the US market for at least another five years, reports Reuters, noting that this delay insulates GSK's $8 billion-a-year money maker for a while longer. It also buys more time for GSK COPD drug Breo Ellipta—Ellipta is the inhaler—to gain traction. The FDA approved Breo Ellipta in May.

Share this article:

Email Newsletters

More in Business Briefs

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.

India's Marck gets FDA Warning Letter

Inspectors of Marck Biosciences found an array of problems during a October-November 2013 inspection, including mold near a sterile area that was so bad "the room had 'partially caved in.'"

DOJ closes Brilinta investigation

AstraZeneca announced the end of the investigation Tuesday.